Polymorphisms of Glucose-Regulated Protein 78 and Risk of Colorectal Cancer: A Case-Control Study in Southwest China

Dan Zhang¹,², Bin Zhou², Yuan Li², Mojin Wang¹,², Cun Wang¹,², Zongguang Zhou¹,², Xiaofeng Sun³

¹ Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China, ² Laboratory of Digestive Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China, ³ Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, County Council of Östergötland, University of Linköping, Linköping, Sweden

Abstract

Glucose-regulated protein 78 (GRP78), an endoplasmic reticulum chaperone, up-regulation serves as an efficient mechanism to promote malignant transformation of colorectal cancer (CRC) and protect CRC cells against apoptosis. Recently, the analysis of GRP78 polymorphisms has already determined that GRP78 rs391957 polymorphism could predict clinical outcome in CRC patients. Thus, we tested whether GRP78 polymorphisms are related to the risk of CRC. In this study, we detected two GRP78 polymorphisms (rs391957 (C>T) and rs430397 (G>A)) in 414 CRC cases and 302 hospital-based cancer-free healthy controls in Southwest China using a polymerase chain reaction–restriction fragment length polymorphism technique. Compared with the CC genotype, carriers of CT and TT genotypes of rs391957 polymorphism had higher risks of CRC (odds ratio (OR) = 1.39, 95% confidence interval (CI) = 1.06–1.83 for CT genotype and OR = 2.10, 95% CI = 1.06–4.14 for TT genotype, respectively). In CRC cases, the variant T allele was significantly associated with tumor invasion stage (P = 0.030), but not with status of lymph nodes metastasis (P = 0.052). Compared with the GG genotype, carriers of GA and AA genotypes of rs430397 polymorphism had higher risks of CRC (OR = 1.63, 95% CI = 1.23–2.15 for GA genotype and OR = 2.92, 95% CI = 1.23–6.94 for AA genotype, respectively). The rs430397 polymorphism was not associated with the clinicopathological characteristics of CRC. These data provide the first evidence that GRP78 rs391957 and rs430397 polymorphisms could serve as markers to predict the risk of CRC.

Introduction

Colorectal cancer (CRC) is the third most common cancer worldwide, accounting for approximately 10% of total cancer cases. Almost 60% of the CRC cases occur in the developed countries [1]. However, the incidence of CRC is increasing in most of the developing countries, whereas trends are either stabilizing or declining in most of the developed countries [2]. As a developing country, China has experienced a two- to four-fold increase in incidence of CRC in recent decades [3]. In addition, the Chinese Hans have significantly higher incidence of CRC than other ethnic groups in Asia [4]. The pathogenesis of CRC is not completely understood but it is surely a multistep carcinogenic process in which genetic and epigenetic alterations accumulate sequentially [3]. Gene polymorphisms as genetic variations have been studied already in more than 35 different genes, and for several genes, association with CRC are observed [6,7].

Glucose-regulated protein 78 (GRP78), also referred to as immunoglobulin heavy chain binding protein, is a member of the heat shock protein 70 family which is constitutively expressed and resides primarily in the endoplasmic reticulum (ER) [8,9]. As a major ER chaperone, GRP78 facilitates protein folding and assembly, translocates newly synthesized polypeptides across the ER membrane, prevents intermediates from aggregating, targets misfolded proteins for proteasome degradation, binds Ca²⁺ and serves as a sensor for ER stress [10–12]. Moreover, overexpression of GRP78 can be dramatically induced by ER stress including glucose deprivation, disturbance of Ca²⁺ homeostasis, oxidative stress and hypoxia, and then triggers the unfolded protein response (UPR). UPR is a complex and multifaceted signal-transduction cascade and serves to limit the accumulation of unfolded proteins, contributing to limiting the damage in cells exposed to ER stress and protecting cells against death [9,12–15].

Cancer cells are often confronted with hypoxia and glucose deprivation, thereby under the condition of ER stress with overexpression of GRP78. Recently, overexpression of GRP78 has been detected in several cancers such as brain cancer, breast cancer, lung cancer, prostate cancer, gastric cancer and CRC. Additionally, GRP78 has been shown to be associated with the development and progression of cancers [16–23]. There were evidences to indicate that GRP78 polymorphisms, alone or in combination, had effect on the expression of GRP78 [24,25]. Previous reports found that GRP78 rs430397 polymorphism was associated with the risk and prognosis of hepatocellular cancer (HCC) and the prognosis of non-small cell lung cancer (NSCLC).
Glucose-Regulated Protein 78 and Colorectal Cancer

Materials and Methods

Study Subjects

A total of 414 CRC cases and 502 cancer-free controls were recruited for this case-control study. The patients were selected sequentially from January 2009 to August 2009 at the department of Gastrointestinal Surgery, West China Hospital, Sichuan University. All the cases had newly diagnosed, untreated primary CRC, who were identified by preoperative colonoscopy and CT scan, intraoperative exploration and postoperative pathological examination. The rectal cancer was regarded as the tumor located within 15 cm distance from the anal, and the non-rectal colon cancer was regarded as the tumor located beyond 15 cm distance from the anal. Patients with other cancer history and previous radiotherapy and chemotherapy were excluded. All the selected cases agreed to participate. The hospital-based controls were randomly selected from the same hospital during routine health checkups, who were cancer-free healthy individuals identified by colonoscopy and CT scan. The control group matched the case group in gender and age. All the participants were unrelated Chinese Hans in Southwest China. Written informed consent, blood samples and clinical data were collected from all the participants according to the protocols approved by the Ethics Committee of West China Hospital of Sichuan University.

DNA Extraction and Genotyping

Genomic DNA was extracted from whole blood of each participant by conventional phenol/chloroform procedure. The concentration and purity of DNA were measured with a spectrophotometer. The isolated DNA was dissolved in TE buffer and stored in the refrigerator at −20°C before analysis. Two GRP78 polymorphisms (rs391957 (C>G) and rs430937 (G>A)) were genotyped using polymerase chain reaction (PCR)–restriction fragment length polymorphism technique. Briefly, forward and reverse primers were used for PCR amplification, and then the amplified products were digested with restriction endonucleases. Furthermore, the lengths of the PCR products and the digested fragments were determined by electrophoresis on 1.5% agarose gel, separately. To genotype GRP78 rs391957 polymorphism, PCR primers were 5'-aattcaggacattgcatcta-3' (forward) and 5'-gtgaaagggagggagaacaa-3' (reverse), and the size of amplified products was 167 bp. The PCR products were then digested with restriction endonuclease HincII. The variant A allele lacked the HincII restriction site and two bands (134 bp and 32 bp) were generated after the digestion. In addition, genotyping results were validated by direct DNA sequencing in a random 5% of samples for quality control. Genotype concordance was 100%.

Association analyses between genotypes distribution of the two GRP78 polymorphisms and clinicopathological characteristics of the CRC cases were evaluated using chi-square test. Risk estimates were calculated for the co-dominant and dominant genetic models using the most common homozygous genotype as the referent category. The effect of genotypes of the GRP78 polymorphisms on the risk of CRC was represented as the odds ratios (ORs) with 95% confidence intervals (CIs) using unconditional logistic regression model adjusted for gender and age. All statistical tests were two sided, and P<0.05 was considered significant. All statistical analyses were performed using the PASW Statistics 18 (SPSS Inc, Chicago, IL).

Characteristics of Study Population

The demographic and clinical characteristics of the study participants were summarized in Table 1. The mean age were 59.0 (±13.2) years and 58.2 (±9.1) years in the cases and controls respectively. Most of the cases and controls were male, and in the cases the gender ratio (male/female) was 1.39:1 while the ratio was 1.5:1 in the controls. There was no significant difference between the cases and controls in terms of age (P = 0.295) and gender (P = 0.092), indicating that our samples could provide adequate power in identifying the association of the risk of CRC with the two GRP78 polymorphisms. The observed genotypes frequency distribution of the two GRP78 polymorphisms in the controls did not show significant deviation from Hardy-Weinberg equilibrium (data not shown).

Association of Clinicopathological Characteristics of the CRC Cases with the Two GRP78 Polymorphisms

Association analyses between genotypes distribution of the two GRP78 polymorphisms and clinicopathological characteristics of the CRC cases were shown in Table 2. Distribution of the variant-allele-carrying genotypes (CT or TT) or CC homozygous genotype of GRP78 rs391957 polymorphism were significantly associated with tumor invasion stage (T1, T2, T3 and T4 stage) in the CRC cases (P = 0.030). Among patients with the variant T allele, 9.0%, 10.1%, 24.9% and 36.0% were in T1, T2, T3 and T4 stage.
Table 1. Baseline demographic and clinical characteristics of CRC cases and controls.

| Characteristic | Cases | Controls | p |
|---------------|-------|----------|---|
|              | N = 414 Frequencies | N = 502 Frequencies |
| Age          | Mean ± SD 59.0±13.2 | 58.2±9.1 | 0.295* |
| Gender       | Males 241 58.2% | 301 60% |
|              | Females 173 41.8% | 201 40% | 0.592a |
| TNM Stage    | I 73 17.7% | |
|              | II 149 36.2% | |
|              | III 139 33.7% | |
|              | IV 51 12.4% | |
| Tumor stage  | T1 34 8.3% | |
|              | T2 55 13.3% | |
|              | T3 80 19.4% | |
|              | T4 243 59% | |
| Lymph node   | Negative 236 57.3% | |
|              | Positive 176 42.7% | |
| Metastasis   | No 361 87.6% | |
|              | Yes 51 12.4% | |
| Tumor site   | Rectum 310 74.9% | |
|              | Colon 104 25.1% | |
| Differentiation | Well 24 6% | |
|              | Moderate 247 61.6% | |
|              | Poor 130 32.4% | |
| Growth pattern | Expansive 150 38.4% | |
|              | Infiltration 241 61.6% | |

*P was computed using t test; 
P was computed using chi-square test.

Among 414 CRC cases, 2 cases had missing data on TNM stage, 13 cases had missing data on tumor differentiation and 23 cases had missing data on tumor growth pattern.

doi:10.1371/journal.pone.0066791.t001

respectively, whereas 7.6%, 16.1%, 14.8% and 61.5% of the patients with the CC homozygous genotype were in T1, T2, T3 and T4 stage respectively. There was a higher trend that the variant T allele carriers had less proportion of lymph nodes metastasis (37.6%) compared with the carriers with CC homozygous genotype (47.1%), although the difference was not statistically significant (P = 0.052). Meanwhile, genotypes distribution of GRP78 rs391957 polymorphism was not associated with other clinicopathological data, such as TNM stage, distant metastasis, tumor site, tumor differentiation and tumor growth pattern in the CRC cases (P > 0.05). In addition, there was also no association between distribution of the variant-allele-carrying genotypes (GA+AA) or GG homozygous genotype of GRP78 rs430397 polymorphism and all the clinicopathological characteristics in the CRC cases (P > 0.05).

Genotypes of the Two GRP78 Polymorphisms were Associated with Increased Risk of CRC

Logistic regression analyses of genotypes of the two GRP78 polymorphisms both showed significant differences between the CRC cases and controls in Table 3. Compared with the CC homozygous genotype of GRP78 rs391957 polymorphism, the CT heterozygous (Adjusted OR = 1.39, 95% CI = 1.06–1.83, P = 0.018) and TT homozygous (Adjusted OR = 2.10, 95% CI = 1.06–4.14, P = 0.033) genotypes were both significantly associated with higher risk of CRC. The overall variant T allele carriers (CT+TT) also had significantly higher risk of CRC compared with the CC homozygous carriers (Adjusted OR = 1.45, 95% CI = 1.11–1.89, P = 0.006), suggesting that the variant T allele of GRP78 rs391957 polymorphism may be a deleterious allele. In addition, similar trend of higher risk of CRC was detected in analyses of genotypes of GRP78 rs430397 polymorphism. Compared with the GG homozygous genotype, the GA heterozygous (Adjusted OR = 1.63, 95% CI = 1.23–2.15, P = 0.001) and AA homozygous (Adjusted OR = 2.92, 95% CI = 1.29–6.94, P = 0.015) genotypes were both significantly associated with higher risk of CRC. The overall variant A allele carriers (GA+AA) also had significantly higher risk of CRC compared with the GG homozygous carriers (Adjusted OR = 1.70, 95% CI = 1.29–2.23, P < 0.001), thus the variant A allele of GRP78 rs430397 polymorphism may be a deleterious allele as well.

Discussion

To our knowledge, this is the first study which has investigated whether GRP78 rs391957 and rs430397 polymorphisms are associated with the risk of CRC. In this hospital-based case-control study, we found that the CT heterozygous, TT homozygous and combined (CT+TT) genotypes of GRP78 rs391957 polymorphism and the GA heterozygous, AA homozygous and combined (GA+AA) genotypes of GRP78 rs430397 polymorphism were both significantly associated with higher risk of CRC in a Chinese Han population, suggesting that the two GRP78 polymorphisms probably play potential roles in the development of CRC.

In the USA, new cases with rectal cancer accounted for approximately 40% of cases with CRC [30]. However, we found that 75% CRCs occurred in the rectum in our cases, which was inconsistent with rectal cancer accounting for 40–50% in overall Han population. Our data was similar to that of the previous study about southwestern Chinese population by Wang et al. where 77% CRCs were rectal cancers in their cases [31]. One possible explanation is the incidence of cancer should be region-specific. Due to the vast territory and large population in China, life style and economic development are different in different regions, with different morbidities for different cancers. For this reason, now that our study focused on southwestern Han population in China, the high proportion of rectal cancer in our cases which might reveal the epidemiological situation of CRC in southwestern Han population was probably different from the proportion of rectal cancer in overall Han population. On the other hand, as southwest China is an economically underdeveloped area, the majority of people in southwest China are unable to afford routine screening for CRC. Therefore, most diagnosed cases were presented as asymptomatic diseases. While rectal cancer may be more obvious than non-rectal colon cancer, patients with rectal cancer have a greater possibility of getting examination and treatment than those
with non-rectal colon cancer. This may be another reason for high proportion of rectal cancer in our cases. Yet despite all this, the definitely proportions of rectal cancer and non-rectal cancer in southwestern Han population would need further investigation in large and multiple-centers studies. Additionally, the ratio of males to females with CRC in our study was 1.39:1, which was also similar to that of 1.36:1 in the previous study about southwestern Chinese population by Wang et al. [31]. Although our ratio in CRC was higher than that in the USA which is usually well balanced between males and females, we considered that the gender ration should also be region-specific because of differences in risk behaviors and ethnic groups. The previous study which showed the lower rates observed among females compared with males may be related to differences in risk behaviors associated with colorectal cancer, such as smoking, and the differing effect of obesity in men and women, also pointed at it [32]. Thus, the higher ratio of males to females with CRC might be the representative of gender ratio in southwestern Chinese population.

It is clear that overexpression of GRP78 occurs in various human cancers and cancer cell lines, correlating with malignancy, metastasis and poor prognosis [13]. The elevated expression of GRP78 increased the WHO pathologic grade of primary astrocytoma, which strongly predicted the patients' prognosis [16]. The expression of GRP78 was up-regulated in prostate cancer cells compared with benign tissue, and the patients with higher expression of GRP78 had almost twice the risk of dying from prostate cancer compared with those with weak expression [20]. GRP78 was highly expressed in gastric cancer and appeared

Table 2. Association of genotypes of GRP78 polymorphisms with clinicopathological characteristics of the CRC cases.

| Characteristic (No. of cases) | GRP78 rs391957 | p* | GRP78 rs430397 | p* |
|------------------------------|----------------|----|----------------|----|
|                              | CC (%)         | CT+TT (%) | GG (%)         | GA+AA (%) |
| Age                         |                |             |                |             |
| <59 (187)                   | 102 (45.7)     | 85 (44.5)   | 116 (47.5)     | 71 (41.8)   |
| ≥59 (227)                   | 121 (54.3)     | 106 (55.5)  | 126 (52.5)     | 99 (58.2)   |
| Gender                      |                | 0.801       |                | 0.245       |
| Males (241)                 | 131 (58.7)     | 110 (57.6)  | 139 (57)       | 102 (60)    |
| Females (173)               | 92 (41.3)      | 81 (42.4)   | 105 (43)       | 68 (40)     |
| TNM Stage                   |                | 0.831       |                | 0.538       |
| I (73)                      | 42 (18.8)      | 31 (16.4)   | 42 (17.4)      | 31 (18.2)   |
| II (149)                    | 71 (31.8)      | 78 (41.3)   | 91 (37.6)      | 58 (34.1)   |
| III (139)                   | 81 (36.3)      | 58 (30.7)   | 82 (33.9)      | 57 (33.5)   |
| IV (51)                     | 29 (13.1)      | 22 (11.6)   | 27 (11.1)      | 24 (14.2)   |
| Tumor stage                 |                | 0.264       |                | 0.780       |
| T1 (34)                     | 17 (7.6)       | 17 (9.0)    | 17 (7.0)       | 17 (10.0)   |
| T2 (55)                     | 36 (16.1)      | 19 (10.1)   | 32 (13.2)      | 23 (13.5)   |
| T3 (80)                     | 33 (14.8)      | 47 (24.9)   | 50 (20.7)      | 30 (17.6)   |
| T4 (243)                    | 137 (61.5)     | 106 (56.0)  | 143 (59.1)     | 100 (58.8)  |
| Lymph node                  |                | 0.052       |                | 0.376       |
| Negative (236)              | 118 (52.9)     | 118 (62.4)  | 143 (59.1)     | 93 (54.7)   |
| Positive (176)              | 105 (47.1)     | 71 (37.6)   | 99 (40.9)      | 77 (45.3)   |
| Metastasis                  |                | 0.002       |                | 0.369       |
| No (361)                    | 194 (87)       | 167 (88.4)  | 215 (88.8)     | 146 (85.9)  |
| Yes (51)                    | 29 (13)        | 22 (11.6)   | 27 (11.2)      | 24 (14.1)   |
| Tumor site                  |                | 0.675       |                | 0.852       |
| Rectum (310)                | 168 (75.3)     | 142 (74.3)  | 182 (74.5)     | 128 (75.3)  |
| Colon (104)                 | 55 (24.7)      | 49 (25.7)   | 62 (25.5)      | 42 (24.7)   |
| Differentiation             |                | 0.817       |                | 0.611       |
| Well (24)                   | 11 (5.1)       | 13 (7.1)    | 14 (6.0)       | 10 (6.0)    |
| Moderate (247)              | 134 (61.7)     | 113 (61.4)  | 148 (63.5)     | 99 (58.9)   |
| Poor (130)                  | 72 (33.2)      | 58 (31.5)   | 71 (30.5)      | 59 (35.1)   |
| Growth pattern              |                | 0.668       |                | 0.389       |
| Expansive (150)             | 83 (39.3)      | 67 (37.2)   | 87 (36.6)      | 67 (40.9)   |
| Infiltration (241)          | 128 (60.7)     | 113 (62.8)  | 144 (63.4)     | 97 (59.1)   |

*p was computed using chi-square test.
Among 414 CRC cases, 2 cases had missing data on TNM stage, 13 cases had missing data on tumor differentiation and 23 cases had missing data on tumor growth pattern.
doi:10.1371/journal.pone.0066791.t002
cells and protect them against apoptosis [23].

expression of GRP78 might enhance the proliferation of CRC

GRP78 inhibited the proliferation of CRC cells and increased the

of GRP78 might be a marker for malignant transformation of

adenoma to colon carcinoma, which indicated that overexpression

histological severity from the normal colon tissue to colon

reported that overexpression of GRP78 appeared to correlate with

risk of HCC and the C allele carriers had higher mRNA and

intervals (CIs) for CRC in relation to genotypes of GRP78

| Genotype | Controls (%) | Cases (%) | OR* (95% CI) | P |
|----------|--------------|-----------|--------------|---|
| GRP78 rs391957 | | | | |
| CC | 315 (63) | 223 (54) | 1 | |
| CT | 172 (34) | 169 (41) | 1.39 (1.06–1.83) | 0.018 |
| TT | 15 (3) | 22 (5) | 2.10 (1.06–4.14) | 0.033 |
| CT+TT | 187 (37) | 191 (46) | 1.45 (1.11–1.89) | 0.006 |
| GRP78 rs430397 | | | | |
| GG | 356 (71) | 244 (59) | 1 | |
| GA | 138 (27) | 154 (37) | 1.63 (1.23–2.15) | 0.001 |
| AA | 8 (2) | 16 (4) | 2.92 (1.23–6.94) | 0.015 |
| GA+AA | 147 (29) | 170 (41) | 1.70 (1.29–2.23) | <0.001 |

*Adjusted for age and gender.
doi:10.1371/journal.pone.0066791.t003

Table 3. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for CRC in relation to genotypes of GRP78 polymorphisms.

to be an independent survival predictor [21]. One previous study reported that overexpression of GRP78 appeared to correlate with histological severity from the normal colon tissue to colon adenoma to colon carcinoma, which indicated that overexpression of GRP78 might be a marker for malignant transformation of CRC [22]. Furthermore, another study showed that knockdown of GRP78 inhibited the proliferation of CRC cells and increased the apoptosis of CRC cells in vitro, which indicated that the expression of GRP78 might enhance the proliferation of CRC cells and protect them against apoptosis [23].

Several studies have demonstrated that the polymorphisms in the promoter of gene are likely to enhance or attenuate the expression of gene [33–35]. The rs391957 polymorphism is located in the promoter of GRP78 gene [24]. It has been noted that the rs391957 polymorphism altered the expression of GRP78 in cells under different conditions. Specifically, in normal cells, the variant T allele carriers had lower basal promoter activity than the CC homozygous carriers. However, in cells under the condition of ER stress, the variant T allele carriers had significantly higher expression of GRP78 than the CC homozygous carriers [25]. Thus, the variant T allele of GRP78 rs391957 polymorphism probably enhances the expression of GRP78 in various cancers thereby affecting the development and progression of cancers. These findings are consistent with the previous study which showed that the CRC patients with the CT heterozygous or TT homozygous genotypes had a significantly higher risk of tumor recurrence compared with the patients with the CC homozygous genotype [27]. Subsequently, our present study has similar findings, which showed that the variant T allele carriers had higher risk of CRC compared with the wild C allele carriers. Collectively, these data provide preliminary support that the variant T allele of GRP78 rs391957 polymorphism may be both a susceptible marker and a prognostic marker for CRC, and have an important function in the development and progression of CRC due to enhancing the expression of GRP78. However, some results still remain contradictory. The latest study showed that the C allele of GRP78 rs391957 polymorphism was associated with increased risk of HCC and the C allele carriers had higher mRNA and protein expression of GRP78 in HCC [29]. The possible explanation is that the conditions of ER stress are different in various types of cancer. Thus, more and further investigations are

needed to discover and confirm the roles of GRP78 rs391957 polymorphism.

We also found that the variant T allele of GRP78 rs391957 polymorphism was associated with local tumor invasion of CRC. However, due to the retrospective design and relative numbers of cases involved, further prospective biomarker embedded clinical trials and cell and tissue experiments will be necessary to validate our result and identify what role the rs391957 polymorphism plays in progression of CRC. In our study, T4 stage was the majority of the cases. Tumor stage is often associated with lack of screening, access to medical care and so on. Thus, our result might also reveal that there is a lack of screening for CRC in southwestern Chinese population. Patients with CRC were unable to get prompt diagnosis, so that the majority of them were at advanced stages when they received proper treatment. It is necessary that southwestern Chinese pay more attention to routine screening for CRC. In addition, the previous study found higher expression of GRP78 contributed to increased lymph node metastasis in gastric cancer patients [21]. In contrast, we found the CRC patients with the variant T allele contributing to higher expression of GRP78 might have less possibility of lymph node metastasis. Limitations of our small sample size are likely to be the reason. Alternatively, the roles of GRP78 in affecting status of lymph node metastasis are different in various cancers.

The variant T allele frequency is approximately 29% in Asian population, 36% in European population, 29% in the USA and only 9% in African population. Thus the fact that most populations share similar proportions of T carriers reinforces the importance of our findings and the need for further study. However, ethnicity is of major importance in polymorphism analysis, and our findings also need studies about other ethnic populations to confirm it in the future.

The polymorphisms in the intron of gene have received less attention, but are beginning to be recognized for their potential contribution to the development and progression of diseases, including cancers [36]. There are splicing enhancer and splicing silencing sites throughout the introns of genes. Sequence alterations in any of these intronic sites can lead to alternation in splicing of the pre-mRNA which contributes to malignant progression [37]. The rs430397 polymorphism is just located in upstream from the intron/exon boundary within the fifth intron of GRP78 gene [36]. The previous study has firstly demonstrated that the variant A allele of GRP78 rs430397 polymorphism was associated with higher risk and poor prognosis of hepatocellular carcinoma [26]. Another study has also demonstrated that the AA homozygous carriers had higher RNA and protein expression of GRP78 compared with the GG homozygous carriers in tissues, and that the AA carriers had poor prognosis of non-small cell lung cancer [28]. The mechanism of GRP78 rs430397 polymorphism affecting the development and progression of cancer is unclear. One hypothesis is that this allele variation in the intron probably alters the splicing of the pre-mRNA, thereby affecting the expression of GRP78 by altering the efficiency of translation or mRNA stability [36]. The result of our study which showed that the variant A allele carriers had higher risk of CRC compared to the CC homozygous carriers has provided indirect evidences to support the hypothesis. Therefore, the variant A allele may be able to enhance the expression of GRP78, but the further function investigation is needed to explain the precise mechanism. Furthermore, the variant A allele of GRP78 rs430397 polymorphism may be a susceptible marker for CRC, but whether the variant A allele is associated with the prognosis of CRC is still not known.
Conclusion

There were significant associations between the risk of CRC and the GRP78 rs391957 and rs430397 polymorphisms. Both the variant T allele of rs391957 polymorphism and the variant A allele and the GRP78 rs391957 and rs430397 polymorphisms were in linkage disequilibrium. Additionally, it was not found that other polymorphisms and rs430397 polymorphism were in linkage disequilibrium.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global Cancer Statistics. Ca Cancer J Clin 61: 69–90.
2. Center MM, Jemal A, Ward E (2009) International Trends in Colorectal Cancer Incidence Rates. Cancer Epidemiol Biomarkers Prev 18: 1680–1689.
3. Sung JJ, Lau JY, Goh KL, Leung WK (2005) Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 6: 871–876.
4. Lee HP, Lee J, Shimmuganathan K (1987) Trends and ethnic variation in incidence and mortality from cancers of the colon and rectum in Singapore, 1968 to 1982. Ann Acad Med Singapore 16: 397–401.
5. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789–799.
6. Houlton RS, Tomlinson IP (2001) Polymorphisms and colorectal tumor risk. Gastroenterology 121: 292–301.
7. Kemp Z, Thirwell C, Sieber O, Silver A, Tomlinson I (2004) An update on the genetics of colorectal cancer. Hum Mol Genet 13: R177–185.
8. Haa HG (1994) BiP (GRP78), an essential hsp70 resident protein in the endoplasmic reticulum. Experientia 50: 1012–1020.
9. Quinones QJ, de Ridder GG, Pizzo SV (2008) GRP78: a chaperone with diverse roles beyond the endoplasmic reticulum. Hum Mol Pathol 23: 1409–1416.
10. Gething MJ (1999) Role and regulation of the ER chaperone BiP. Semin Cell Dev Biol 10: 465–472.
11. Lee AS (2001) The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 26: 504–510.
12. Hendershot LM (2004) The ER function BiP is a master regulator of ER function. Mt Sinai J Med 71: 289–297.
13. Li J, Lee AS (2000) Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 6: 45–54.
14. Ma Y, Hendershot LM (2004) The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 4: 966–977.
15. Lee AS (2005) The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 35: 373–381.
16. Zhang LH, Yang XL, Zhang W, Cheng JX, Zhang W (2011) Association of elevated GRP78 expression with increased astrocytoma malignancy via Akt and ERK pathways. Brain Res 1371: 23–31.
17. Fernandez PM, Tabbara SO, Jacobs LK, Manning FC, Tsangaris TN, et al. (2000) Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 59: 15–26.
18. Uramoto H, Sugio K, Oyama T, Nakata S, Uno K, et al. (2005) Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 49: 53–62.
19. Koomagi R, Matern J, Volm M (1999) Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LRP56 and angiogenesis in non-small cell lung carcinomas. Anticancer Res 19: 4333–4336.
20. Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, et al. (2007) Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol 38: 1547–1552.
21. Zhang J, Jiang Y, Jia Z, Li L, Gong W, et al. (2006) Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis 23: 401–410.
22. Xing X, Tai M, Wang Y, Xu E, Huang Q (2006) Overexpression of glucose-regulated protein 78 in colon cancer. Clin Chim Acta 364: 308–315.
23. Xing X, Li Y, Liu H, Wang L, Sun L (2011) Glucose regulated protein 78 (GRP78) is overexpressed in colorectal carcinoma and regulates colorectal carcinoma cell growth and apoptosis. Acta Histochem 113: 777–782.
24. Kakuchi C, Ishiwata M, Nanko S, Kumiogi H, Minabe Y, et al. (2005) Function polymorphisms of HSPA1A: possible association with bipolar disorder. Biochem Biophys Res Commun 336: 1136–1143.
25. Hsi WC, Wang HK, Lee LC, Fung HC, Lin JC, et al. (2008) Promoter polymorphisms modulating HSPA5 expression may increase susceptibility to Taiwanese Alzheimer’s disease. J Neural Transm 115: 1537–1543.
26. Zhu X, Chen MS, Tian IW, Li DP, Xu PL, et al. (2009) Single nucleotide polymorphism of rs430397 in the fifth intron of GRP78 gene and clinical relevance of primary hepatocellular carcinoma in Han Chinese: risk and prognosis. Int J Cancer 125: 1352–1357.
27. Zhu X, Lin MC, Fan W, Tian L, Wang J, et al. (2012) An intronic polymorphism in GRP78 improves chemotherapeutic prediction in non-small cell lung cancer. Chest 141: 1466–1472.
28. Winder T, Bohanes P, Zhang W, Yang D, Power DG, et al. (2011) GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients. Ann Oncol 22: 2431–2439.
29. Zhu X, Zhang JF, Fan WQ, Wang F, Yao H, et al. (2013) The rs391957 variant caregulating onecogene GRP78 expression contributes to the risk of hepatocellular carcinoma. Carcinogenesis.
30. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60: 277–300.
31. Wang MJ, Zhou ZG, Wang L, Yu YY, Zhang P, et al. (2009) The Ile646Val (2073A>G) polymorphism in the kinase binding domain of the A-kinase anchoring protein 10 and the risk of colorectal cancer. Oncology 76: 199–204.
32. Center MM, Jemal A, Smith RA, Ward E (2009) Worldwide Variations in Colorectal Cancer. Ca Cancer J Clin 59: 366–370.
33. Dewan A, Liu M, Hartman S, Zhang SS, Liu DT, et al. (2006) HTRA1 anchoring protein 10 and the risk of colorectal cancer. Oncology 76: 277–300.
34. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591–602.
35. Makela R, Lomboala A, Neuenen A, Mercuri M, Vuori I, et al. (2008) The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes. Clin Biochem 41: 532–537.
36. Merrick DT (2012) GRP78, intronic polymorphisms, and pharmacogenomics in non-small cell lung cancer. Chest 141: 1377–1378.
37. Faustino NA, Cooper TA (2005) Pre-mRNA splicing and human disease. Genes Dev 17: 419–437.